TB-500 (Thymosin Beta-4) vs KPV: what the research actually compares
A research-only comparison of TB-500 (thymosin beta-4 17-23 fragment) and KPV (lysine-proline-valine), covering what each is, what published work measured, where evidence is stronger, and what remains unknown.
TB-500 is the 17-23 fragment of thymosin beta-4, a synthetic peptide corresponding to the actin-binding domain of the parent protein. Synonyms include thymosin beta-4 17-23 fragment and TB4 17-23. The evidence block does not provide a sequence, molecular formula, or molecular weight for TB-500. KPV is lysine-proline-valine, an endogenous tripeptide derived from alpha-melanocyte-stimulating hormone. The evidence block does not provide a molecular formula or molecular weight for KPV. Both are peptides, but they belong to different structural classes: TB-500 is a fragment of a larger actin-sequestering protein, while KPV is a short cleavage product of a pro-opiomelanocortin-derived hormone.
The published work on TB-500 centres on vascular function and inflammation biomarkers in stable atherosclerotic cardiovascular disease [1]. The published work on KPV centres on reactive oxygen species (ROS)-mediated signalling, including AKT/mTORC1/PPARγ and PPARγ-dependent pathways, in adipocyte and hepatic cell models [3][4], and on gastrointestinal stability and ROS-responsive release in oral peptide delivery systems [2].
Research Studies
TB-500 and cardiovascular biomarkers in stable ASCVD
A Phase 1/2 trial record describes an evaluation of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD) [1]. The record lists safety and tolerability as the primary focus, with exploratory endpoints assessing vascular function and inflammation biomarkers [1]. The population is adults with stable ASCVD. The record does not report results, effect sizes, or statistical outcomes; it is a study description, not a completed analysis.
KPV and adipogenesis in cell models
One study investigated the regulatory effects of KPV on MDI-induced adipocyte differentiation [3]. The work reports that KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signalling [3]. The model is an in vitro adipocyte differentiation system. The findings are limited to that experimental context; no human or animal data are described in the evidence block for this endpoint.
KPV and hepatic lipid accumulation in HepG2 cells
A separate study examined the protective role of KPV in hepatocellular steatosis, an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum characterised by excessive lipid accumulation and oxidative stress [4]. Using HepG2 cells, the work reports that KPV attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway [4]. The model is a human hepatoma cell line. The evidence block does not describe animal or clinical confirmation of this effect.
KPV and oral peptide delivery across gastrointestinal barriers
A self-immolative peptide prodrug conjugate (SIPPC) platform was developed for inflammation-targeted oral delivery, integrating a hydrophilic polyethylene glycol segment, a ROS-responsive hydrophobic self-immolative module, and a hydrolyzable scaffold that together enable spontaneous assembly into micelle-like nanoparticles [2]. Using three anti-inflammatory peptides, including KPV, the engineered conjugates exhibited gastrointestinal stability, efficient mucus penetration, and ROS-responsive release at inflamed sites [2]. This work addresses delivery chemistry and barrier crossing, not the intrinsic pharmacological activity of KPV in a disease model.
TB-500 and KPV in the context of peptide doping review
A critical review of peptide and peptide-analog drug use in recreational and professional sport and bodybuilding describes the shift from anabolic-androgenic steroids to peptides marketed as more selective alternatives [5]. The review names growth hormone secretagogues such as ipamorelin among the agents discussed [5]. The evidence block does not state that TB-500 or KPV are named in that review, and no sport-related finding for either compound is reported here. This source is included only to indicate the broader regulatory and anti-doping context in which peptide research is sometimes discussed.
KPV and host defense peptides in inflammatory bowel disease
A short review of host defense peptides (HDPs) describes them as emerging candidates for inflammatory bowel disease (IBD), a chronic disorder of the gastrointestinal tract causing severe inflammation and tissue damage, where current treatments often have adverse effects [6]. The evidence block does not state that KPV is classified as a host defense peptide or that it is discussed in this review. No specific finding for KPV in IBD is reported here. This source is included only to indicate the review-level interest in peptides for gastrointestinal inflammation.
TB-500 and KPV: direct comparative data
The evidence block contains no study that administers TB-500 and KPV in the same experiment, model, or population. There is no head-to-head pharmacokinetic, pharmacodynamic, or safety comparison. Any statement that one compound is more effective, safer, or better absorbed than the other would not be supported by the sources provided.
TB-500 and KPV: what the evidence does not cover
For TB-500, the evidence block provides a single trial record in stable ASCVD with safety and tolerability as the focus and exploratory biomarker endpoints [1]. No results, no dose, no duration, and no comparator beyond placebo are described. For KPV, the evidence block provides in vitro studies in adipocyte and HepG2 cell models [3][4] and a delivery-chemistry study using KPV as one of three payload peptides [2]. No clinical trial record for KPV appears in the evidence block. Neither compound has published comparative data in the sources provided.
Comparison table
| Feature | TB-500 (Thymosin Beta-4 17-23 Fragment) | KPV (Lysine-Proline-Valine) |
|---|---|---|
| Formal name | Thymosin beta-4 17-23 fragment | Lysine-proline-valine |
| Synonyms | TB4 17-23, TB-500 | KPV tripeptide |
| Class | Fragment of thymosin beta-4 | Endogenous tripeptide derived from alpha-melanocyte-stimulating hormone |
| Sequence / formula / MW | Not provided in evidence block | Not provided in evidence block |
| Pathway or receptor family in cited work | Vascular function and inflammation biomarkers [1] | ROS-mediated AKT/mTORC1/PPARγ and PPARγ-dependent pathways [3][4] |
| Study types in evidence block | Phase 1/2 trial record (safety/tolerability; exploratory biomarkers) [1] | In vitro adipocyte differentiation [3]; HepG2 hepatocellular steatosis [4]; oral delivery platform [2] |
| Population or model | Adults with stable ASCVD [1] | Adipocyte differentiation model [3]; HepG2 cells [4]; nanoparticle delivery system [2] |
| Reported outcomes | None reported in evidence block; record describes endpoints only [1] | Attenuation of adipogenesis and lipid metabolism [3]; attenuation of hepatic lipid accumulation [4]; GI stability, mucus penetration, ROS-responsive release [2] |
| Direct head-to-head data | None in evidence block | None in evidence block |
Where the evidence is stronger for one compound
For TB-500, the evidence block contains a clinical trial record in a defined patient population with specified exploratory endpoints [1]. That is a higher level of clinical description than anything provided for KPV. However, the record does not report results, so it supports the existence of a clinical research programme, not a finding of efficacy or safety.
For KPV, the evidence block contains multiple in vitro studies reporting specific molecular and cellular outcomes [3][4], plus a delivery-chemistry study demonstrating gastrointestinal stability and ROS-responsive release in a nanoparticle system [2]. These are mechanistic and formulation findings. They do not establish clinical effect, and they are not directly comparable to a clinical trial record.
Neither compound has an advantage in the evidence block that can be stated as a comparative fact. The TB-500 evidence is clinical in setting but unreported in outcome; the KPV evidence is mechanistic and in vitro but reports specific measured effects. The two bodies of work answer different questions.
What is simply not known
- No sequence, molecular formula, or molecular weight is provided for either compound in the evidence block.
- No pharmacokinetic data for TB-500 or KPV appear in the evidence block.
- No dose-response data for either compound appear in the evidence block.
- No results from the TB-500 trial record are reported in the evidence block [1].
- No clinical trial record for KPV appears in the evidence block.
- No study in the evidence block compares TB-500 and KPV directly.
- No long-term safety data for either compound appear in the evidence block.
- No data on human absorption, distribution, metabolism, or excretion for either compound appear in the evidence block.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — ClinicalTrials.gov
- [2] Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. — europe_pmc
- [3] KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. — europe_pmc
- [4] Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. — europe_pmc
- [5] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — europe_pmc
- [6] Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease. — europe_pmc